E3 ubiquitin ligase FBXO22 inhibits SARS‐CoV‐2 replication via promoting proteasome‐dependent degradation of NSP5
Journal of Medical Virology · 2024
DOI: 10.1002/jmv.29891 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medical Virology, 2024. Verfasst von Yuzheng Zhou und 9 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital, The Second Affiliated Hospital,…. Hauptthemen laut MEDLINE: Virus Replication, Ubiquitination, Proteasome Endopeptidase Complex, SARS-CoV-2. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 53 Literaturangaben. Gefördert von: National Key Research and Development Program of China, Chinese Academy of Medical Sciences Clinical and Translational Medicine Research Project, Major Project of Guangzhou National Laboratory.
Abstract (Originalsprache)
The ubiquitin‐proteasome system is frequently employed to degrade viral proteins, thereby inhibiting viral replication and pathogenicity. Through an analysis of the degradation kinetics of all the SARS‐CoV‐2 proteins, our study revealed rapid degradation of several proteins, particularly NSP5. Additionally, we identified FBXO22, an E3 ubiquitin ligase, as the primary regulator of NSP5 ubiquitination. Moreover, we validated the interaction between FBXO22 and NSP5, demonstrating that FBXO22‐mediated ubiquitination of NSP5 facilitated its recognition by the proteasome, leading to subsequent degradation. Specifically, FBXO22 catalyzed the formation of K48‐linked polyubiquitin chains on NSP5 at lysine residues 5 and 90. Knockdown of FBXO22 resulted in decreased NSP5 ubiquitination levels, increased stability, and enhanced ability to evade the host innate immune response. Notably, the protein level of FBXO22 were negatively correlated with SARS‐CoV‐2 load, highlighting its importance in inhibiting viral replication. This study elucidates the molecular mechanism by which FBXO22 mediates the degradation of NSP5 and underscores its critical role in limiting viral replication. The identification of FBXO22 as a regulator of NSP5 stability provides new insights and potential avenues for targeting NSP5 in antiviral strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute for Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital, The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Sh…
- Shenzhen Research Center for Communicable Disease Diagnosis and Treatment, Chinese Academy of Medical Sciences, Shenzhen, China.
ORCID-Profile: Zheng Zhang
Förderung
- National Key Research and Development Program of China
- Chinese Academy of Medical Sciences Clinical and Translational Medicine Research Project
- Major Project of Guangzhou National Laboratory
- The National Science Fund for Distinguished Young Scholars
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation
- Guangdong Science and Technology Plan Project, Construction of high-level biosafety laboratories
- Shenzhen Science and Technology Program
Zitieren
APA
Zhou, Y., Feng, W., Yang, C., Wei, X., Fan, L., Wu, Y., Gao, X., Shen, X., Zhang, Z., & Zhao, J. (2024). E3 ubiquitin ligase FBXO22 inhibits SARS‐CoV‐2 replication via promoting proteasome‐dependent degradation of NSP5. Journal of Medical Virology. https://doi.org/10.1002/jmv.29891
Vancouver
Zhou Y, Feng W, Yang C, Wei X, Fan L, Wu Y, et al. E3 ubiquitin ligase FBXO22 inhibits SARS‐CoV‐2 replication via promoting proteasome‐dependent degradation of NSP5. Journal of Medical Virology. 2024. doi:10.1002/jmv.29891
BibTeX
@article{Zhou2024,
author = {Zhou, Yuzheng and Feng, Wei and Yang, Chuwei and Wei, Xiafei and Fan, Lujie and Wu, Yezi and Gao, Xiang and Shen, Xiaotong and Zhang, Zheng and Zhao, Juanjuan},
title = {E3 ubiquitin ligase FBXO22 inhibits SARS‐CoV‐2 replication via promoting proteasome‐dependent degradation of NSP5},
journal = {Journal of Medical Virology},
year = {2024},
doi = {10.1002/jmv.29891}
}
EUVIMED